Posted by Michael Wonder on 30 Jul 2022
FDA approves Arcutis Zoryve (roflumilast) 0.3% cream for the treatment of plaque psoriasis in individuals age 12 and older
29 July 2022 - Commercial product expected to be available by mid August.
Arcutis Biotherapeutics announced today that the U.S. FDA has approved the new drug application for Zoryve (roflumilast) cream 0.3% for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older.
